CY1105587T1 - Ισοϊνδολινο-1 -ονη-ενεργοποιητες γλυκοκινασης - Google Patents
Ισοϊνδολινο-1 -ονη-ενεργοποιητες γλυκοκινασηςInfo
- Publication number
- CY1105587T1 CY1105587T1 CY20051101133T CY051101133T CY1105587T1 CY 1105587 T1 CY1105587 T1 CY 1105587T1 CY 20051101133 T CY20051101133 T CY 20051101133T CY 051101133 T CY051101133 T CY 051101133T CY 1105587 T1 CY1105587 T1 CY 1105587T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- carbon atom
- ring
- mono
- carbon atoms
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 229910052757 nitrogen Chemical group 0.000 abstract 2
- 102000030595 Glucokinase Human genes 0.000 abstract 1
- 108010021582 Glucokinase Proteins 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- -1 Propanamide-substituted isoindolin-1-one Chemical class 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25527300P | 2000-12-13 | 2000-12-13 | |
| US31871501P | 2001-09-13 | 2001-09-13 | |
| PCT/EP2001/014404 WO2002048106A2 (en) | 2000-12-13 | 2001-12-07 | Isoindolin-1-one glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105587T1 true CY1105587T1 (el) | 2010-07-28 |
Family
ID=26944583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20051101133T CY1105587T1 (el) | 2000-12-13 | 2005-09-15 | Ισοϊνδολινο-1 -ονη-ενεργοποιητες γλυκοκινασης |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6482951B2 (https=) |
| EP (1) | EP1349856B1 (https=) |
| JP (1) | JP4021766B2 (https=) |
| KR (1) | KR100520651B1 (https=) |
| CN (1) | CN1247574C (https=) |
| AT (1) | ATE297922T1 (https=) |
| AU (2) | AU3841502A (https=) |
| BG (1) | BG107903A (https=) |
| BR (1) | BR0116169A (https=) |
| CA (1) | CA2430579C (https=) |
| CY (1) | CY1105587T1 (https=) |
| CZ (1) | CZ20031882A3 (https=) |
| DE (1) | DE60111570T2 (https=) |
| DK (1) | DK1349856T3 (https=) |
| EG (1) | EG24358A (https=) |
| ES (1) | ES2243578T3 (https=) |
| HR (1) | HRP20030450B1 (https=) |
| HU (1) | HUP0400587A3 (https=) |
| IL (2) | IL156264A0 (https=) |
| MA (1) | MA26973A1 (https=) |
| MX (1) | MXPA03005170A (https=) |
| MY (1) | MY136741A (https=) |
| NO (1) | NO325810B1 (https=) |
| NZ (1) | NZ526236A (https=) |
| PA (1) | PA8534601A1 (https=) |
| PE (1) | PE20020593A1 (https=) |
| PL (1) | PL366006A1 (https=) |
| PT (1) | PT1349856E (https=) |
| RS (1) | RS50933B (https=) |
| RU (1) | RU2249590C2 (https=) |
| SI (1) | SI1349856T1 (https=) |
| SK (1) | SK8732003A3 (https=) |
| TW (1) | TWI294876B (https=) |
| UY (1) | UY27069A1 (https=) |
| WO (1) | WO2002048106A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| RU2309956C2 (ru) | 2002-10-03 | 2007-11-10 | Ф.Хоффманн-Ля Рош Аг | Производные индол-3-карбоксамида в качестве активаторов глюкокиназы |
| BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| WO2004072066A1 (en) * | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
| US7750020B2 (en) | 2004-04-02 | 2010-07-06 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes |
| AU2005229415B2 (en) * | 2004-04-02 | 2009-05-14 | Novartis Ag | Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
| CA2614746C (en) | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| CA2621227A1 (en) * | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| JP2009509988A (ja) | 2005-09-29 | 2009-03-12 | サノフィ−アベンティス | フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用 |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| WO2007053662A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
| WO2007053503A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| CA2627910A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
| WO2007053657A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
| JP2009514835A (ja) * | 2005-11-03 | 2009-04-09 | プロシディオン・リミテッド | トリシクロ置換型アミド |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| US8034822B2 (en) | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP2049518B1 (en) * | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| WO2008074694A1 (en) * | 2006-12-20 | 2008-06-26 | F. Hoffmann-La Roche Ag | Crystallization of glucokinase activators |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| TW200831081A (en) * | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| MX2009009525A (es) * | 2007-03-07 | 2009-09-16 | Kyorin Seiyaku Kk | Activador de glucocinasa. |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20091313A1 (es) * | 2008-01-15 | 2009-09-03 | Lilly Co Eli | (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina |
| KR20100110367A (ko) * | 2008-01-24 | 2010-10-12 | 메르크 파텐트 게엠베하 | 당뇨병 치료를 위한 베타-아미노산 유도체들 |
| SI2275414T1 (sl) | 2008-04-28 | 2015-10-30 | Kyorin Pharmaceutical Co., Ltd., | Ciklopentilakrilamidni derivat |
| BRPI0912802A2 (pt) * | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| KR101258331B1 (ko) * | 2008-09-11 | 2013-04-26 | 화이자 인코포레이티드 | 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도 |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| US8178689B2 (en) * | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| ES2664873T3 (es) | 2011-03-01 | 2018-04-23 | Synergy Pharmaceuticals Inc. | Proceso de preparación de agonistas de guanilato ciclasa C |
| US8470866B2 (en) * | 2011-05-03 | 2013-06-25 | Hoffmann-La Roche Inc. | Isoindolinone derivatives |
| SI3004076T1 (sl) * | 2013-05-27 | 2020-02-28 | F. Hoffmann-La Roche Ag | Novi spojini 3,4-dihidro-2H-izokinolin-1-on in 2,3-dihidro-izoindol-1-on |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| KR102431436B1 (ko) | 2014-08-29 | 2022-08-10 | 테스 파마 에스.알.엘. | α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제 |
| AR109950A1 (es) | 2016-10-14 | 2019-02-06 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| AR117122A1 (es) | 2018-11-20 | 2021-07-14 | Tes Pharma S R L | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA |
| CN116283717B (zh) * | 2023-01-06 | 2025-04-08 | 暨南大学 | 一种藁本内酯衍生物及其制备方法和应用 |
| WO2024229228A2 (en) * | 2023-05-02 | 2024-11-07 | The Rockefeller University | 1-oxoisoindolin-2-yl amide activators of vcp and derivatives thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2687147A1 (fr) * | 1992-02-11 | 1993-08-13 | Union Pharma Scient Appl | Nouveaux derives d'alpha-amino n-pyridyl benzene propanamide, leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| CA2224062C (en) * | 1995-06-06 | 2001-09-04 | Pfizer Limited | Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors |
| SI1169312T1 (en) | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
| AU2001252270B2 (en) | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| AU778036B2 (en) | 2000-05-08 | 2004-11-11 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
-
2001
- 2001-12-06 US US10/010,978 patent/US6482951B2/en not_active Expired - Fee Related
- 2001-12-07 AU AU3841502A patent/AU3841502A/xx active Pending
- 2001-12-07 CA CA2430579A patent/CA2430579C/en not_active Expired - Fee Related
- 2001-12-07 CN CNB018206107A patent/CN1247574C/zh not_active Expired - Fee Related
- 2001-12-07 JP JP2002549637A patent/JP4021766B2/ja not_active Expired - Fee Related
- 2001-12-07 KR KR10-2003-7007869A patent/KR100520651B1/ko not_active Expired - Fee Related
- 2001-12-07 SI SI200130381T patent/SI1349856T1/xx unknown
- 2001-12-07 PL PL01366006A patent/PL366006A1/xx unknown
- 2001-12-07 HR HR20030450A patent/HRP20030450B1/xx not_active IP Right Cessation
- 2001-12-07 NZ NZ526236A patent/NZ526236A/xx unknown
- 2001-12-07 ES ES01986857T patent/ES2243578T3/es not_active Expired - Lifetime
- 2001-12-07 AT AT01986857T patent/ATE297922T1/de active
- 2001-12-07 RU RU2003120512/04A patent/RU2249590C2/ru not_active IP Right Cessation
- 2001-12-07 SK SK873-2003A patent/SK8732003A3/sk unknown
- 2001-12-07 MX MXPA03005170A patent/MXPA03005170A/es active IP Right Grant
- 2001-12-07 HU HU0400587A patent/HUP0400587A3/hu unknown
- 2001-12-07 DE DE60111570T patent/DE60111570T2/de not_active Expired - Lifetime
- 2001-12-07 DK DK01986857T patent/DK1349856T3/da active
- 2001-12-07 CZ CZ20031882A patent/CZ20031882A3/cs unknown
- 2001-12-07 IL IL15626401A patent/IL156264A0/xx unknown
- 2001-12-07 PT PT01986857T patent/PT1349856E/pt unknown
- 2001-12-07 EP EP01986857A patent/EP1349856B1/en not_active Expired - Lifetime
- 2001-12-07 RS YUP-477/03A patent/RS50933B/sr unknown
- 2001-12-07 AU AU2002238415A patent/AU2002238415B2/en not_active Ceased
- 2001-12-07 WO PCT/EP2001/014404 patent/WO2002048106A2/en not_active Ceased
- 2001-12-07 BR BR0116169-5A patent/BR0116169A/pt not_active Application Discontinuation
- 2001-12-10 EG EG20011316A patent/EG24358A/xx active
- 2001-12-10 TW TW090130510A patent/TWI294876B/zh not_active IP Right Cessation
- 2001-12-10 PA PA20018534601A patent/PA8534601A1/es unknown
- 2001-12-11 PE PE2001001234A patent/PE20020593A1/es not_active Application Discontinuation
- 2001-12-11 MY MYPI20015613A patent/MY136741A/en unknown
- 2001-12-12 UY UY27069A patent/UY27069A1/es not_active Application Discontinuation
-
2003
- 2003-06-02 IL IL156264A patent/IL156264A/en not_active IP Right Cessation
- 2003-06-12 MA MA27197A patent/MA26973A1/fr unknown
- 2003-06-12 NO NO20032674A patent/NO325810B1/no not_active IP Right Cessation
- 2003-06-13 BG BG107903A patent/BG107903A/bg unknown
-
2005
- 2005-09-15 CY CY20051101133T patent/CY1105587T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105587T1 (el) | Ισοϊνδολινο-1 -ονη-ενεργοποιητες γλυκοκινασης | |
| MXPA03005119A (es) | Activadores de glucoquinasa heteroaromaticos fusionados. | |
| CY1116298T1 (el) | Ενωσεις 3,4-διυποκατεστημενου 1η-πυραζολιου και χρηση αυτων ως ρυθμιστες κινασων που εξαρτωνται απο κυκλινη (cdk) και κινασης-3 συνθασης γλυκογονου (gsk-3) | |
| ES2301859T3 (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| CO5611111A2 (es) | Inhibidores de la histona desacetilasa | |
| CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
| AR041467A1 (es) | Indol-3-carboxamidas como activadores de glucoquinasa (gk) | |
| MY118904A (en) | 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents | |
| CO6140058A2 (es) | Derivados de 2-pirazinona para el tratamiento de la enfermedad o condicion en la cual es benefica la inhibición de la actividad elastasa de neutrofilos | |
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| WO2006109085A8 (en) | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 | |
| DK0383449T3 (da) | Heterocykliske forbindelser | |
| EA200001172A1 (ru) | Терапевтические диарильные производные | |
| ECSP10010158A (es) | Derivados de piridina. | |
| WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
| AR063529A1 (es) | Compuestos de pirazolina | |
| UA66756C2 (uk) | Сполуки піперазину та піперидину, спосіб одержання сполук та спосіб лікування розладів центральної нервової системи | |
| NO954762D0 (no) | Nye tiazolindindioner og legemiddel inneholdende slike | |
| TW237450B (https=) | ||
| CY1110284T1 (el) | Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο | |
| BR0109552A (pt) | Corantes do complexo de metal tris-azo pretos | |
| WO2003004497A1 (en) | Novel heterocyclic compound | |
| AR039122A1 (es) | Derivados de ftalimido como inhibidores de monoamino oxidasa b | |
| FI972661A0 (fi) | Monilääkeresistanssia moduloivat piperatsiini-2,5-dionijohdannaiset |